^
    Back
    Association details:
    Biomarker:NTRK3 fusion
    Cancer:Pancreatic Cancer
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…Treatment Options After First-Line Therapy…In patients with tumors harboring NTRK fusions, treatment with larotrectinib or entrectinib is recommended…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Excerpt:
    ROZLYTREK is a kinase inhibitor indicated for the treatment of...Adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO-GI 2020
    Title:

    O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)

    Published date:
    07/08/2020
    Excerpt:
    The cohort of patients with NTRK-fp gastrointestinal cancers comprised 12 adults (1 cholangiocarcinoma; 7 colorectal carcinomas; 3 pancreatic cancers; 1 other)...entrectinib continues to demonstrate a high level of clinical benefit for patients with NTRK-fp solid tumors, and a manageable safety profile, including patients with a variety of gastrointestinal cancers.
    DOI:
    https://doi.org/10.1016/j.annonc.2020.04.056